ERBITUX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ERBITUX (ERBITUX).
Cetuximab is a chimeric monoclonal IgG1 antibody that binds specifically to the extracellular domain of the epidermal growth factor receptor (EGFR), competitively inhibiting ligand binding and subsequent receptor dimerization and autophosphorylation, thereby blocking downstream signaling pathways involved in cell proliferation, survival, and angiogenesis.
| Metabolism | Cetuximab undergoes proteolytic degradation into small peptides and amino acids via general protein catabolism. It does not rely on hepatic CYP450 enzymes for clearance. |
| Excretion | Cetuximab is not metabolized by the liver or excreted renally; elimination occurs primarily via binding to target cells and subsequent degradation. Less than 1% is excreted unchanged in urine or feces. |
| Half-life | Terminal elimination half-life is approximately 112 hours (range 75–188 hours) following multiple doses, supporting weekly dosing intervals. |
| Protein binding | Approximately 90% bound to plasma proteins (primarily albumin and immunoglobulins). |
| Volume of Distribution | Volume of distribution at steady state is approximately 2.3 L/m² (equivalent to ~0.06 L/kg in a typical adult), indicating limited extravascular distribution consistent with a monoclonal antibody confined primarily to plasma and interstitial spaces. |
| Bioavailability | Bioavailability is 100% following intravenous administration; no other routes are clinically used. |
| Onset of Action | After intravenous infusion, clinical effects (e.g., tumor regression, inhibition of EGFR signaling) are typically observed within 2–4 weeks, based on radiographic or symptomatic response. |
| Duration of Action | Suppression of EGFR signaling persists for the duration of treatment (weekly dosing). After cessation, effects wane over several weeks consistent with the half-life. Duration is limited by the treatment interval and tumor resistance. |
Cetuximab 400 mg/m2 IV over 120 minutes initial dose, then 250 mg/m2 IV over 60 minutes weekly.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment recommended for renal impairment. Data insufficient for GFR-based modifications. |
| Liver impairment | No dose adjustment recommended for hepatic impairment. Data insufficient for Child-Pugh based modifications. |
| Pediatric use | Safety and efficacy not established. No approved pediatric dosing. |
| Geriatric use | No specific dose adjustment for elderly patients. Monitor for infusion reactions and electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ERBITUX (ERBITUX).
| Breastfeeding | It is unknown whether cetuximab is excreted in human milk. Human IgG is present in breast milk, but concentrations are typically low. Due to potential for serious adverse reactions in the breastfed infant, advise women not to breastfeed during treatment and for at least 2 months after the last dose. M/P ratio not established. |
| Teratogenic Risk | Erbitux (cetuximab) is an IgG1 monoclonal antibody. Based on its mechanism of action (EGFR inhibition), it is expected to cause fetal harm when administered to a pregnant woman. Human IgG crosses the placental barrier, and EGFR is implicated in embryonic development. First trimester exposure may increase risk of structural anomalies; second and third trimester exposure may cause oligohydramnios, fetal renal impairment, and neonatal toxicity. Contraindicated in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
WARNING: INFUSION REACTIONS: Serious and fatal infusion reactions have been reported; monitor during infusion and have resuscitation equipment available. CARDIOVASCULAR: In a randomized trial, the addition of cetuximab to radiation therapy plus cisplatin increased the incidence of grade 3-4 cardiac events (including myocardial infarction, arrhythmia, and heart failure) compared to radiation and cisplatin alone.
| Serious Effects |
["Known severe hypersensitivity to cetuximab or any of its excipients."]
| Precautions | ["Infusion reactions: severe anaphylactoid reactions requiring immediate discontinuation.","Cardiopulmonary arrest: increased risk in HNSCC patients receiving cetuximab with radiation; monitor electrolytes and cardiac function.","Dermatologic toxicity: acneiform rash; monitor for severe reactions requiring dose modification.","Hypomagnesemia and electrolyte abnormalities: monitor magnesium, calcium, and potassium levels.","Interstitial lung disease (ILD): discontinue if confirmed.","Ocular toxicity: including conjunctivitis, blepharitis, and keratitis.","Pregnancy: may cause fetal harm."] |
Loading safety data…
| Fetal Monitoring | Monitor for infusion reactions, dermatologic toxicity, and electrolyte disturbances (especially hypomagnesemia, hypocalcemia, hypokalemia). If used during pregnancy, monitor fetal growth and amniotic fluid volume via ultrasound. Assess for signs of oligohydramnios. Evaluate newborn for renal function and electrolyte abnormalities. |
| Fertility Effects | Cetuximab may impair fertility in females based on animal studies (disrupted follicular development). No human data on male fertility. Potential for reduced reproductive capacity. |